"10.1371_journal.pone.0100948","plos one","2014-06-24T00:00:00Z","Ming V Li; Dip Shukla; Brian H Rhodes; Anjali Lall; Jingmin Shu; Branden S Moriarity; David A Largaespada","Division of Endocrinology and Diabetes, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America; Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, Minnesota, United States of America; Department of Agronomy and Plant Genetics, University of Minnesota, St. Paul, Minnesota, United States of America; Center for Genome Engineering and Institute of Human Genetics, University of Minnesota, Minneapolis, Minnesota, United States of America; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America","Conceived and designed the experiments: MVL DAL. Performed the experiments: MVL DS BHR AL JS BSM. Analyzed the data: MVL DAL. Contributed reagents/materials/analysis tools: MVL DAL. Wrote the paper: MVL.","The authors have read the journals policy and have the following conflicts: DAL is a consultant, co-founder, and equity holder of NeoClone Biotechnology, Inc., a company providing antibodies to its customers. DAL is a consultant, co-founder, and equity holder of Discovery Genomics, Inc., a company pursuing human gene therapy. DAL has collaborative research agreements with Novartis and Genentech. Genentech is funding a research project in his laboratory. The contents of this manuscript are unrelated to all of the companies mentioned above. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2014","06","Ming V Li","MVL",7,TRUE,2,6,2,1,TRUE,TRUE,FALSE,0,NA,FALSE
